Revolution Medicines: Clinical Momentum and Strategic Phase 3 Design Support Buy Rating on RVMD

J.P. Morgan analyst Brian Cheng has maintained their bullish stance on RVMD stock, giving a Buy rating today.

Brian Cheng has given his Buy rating due to a combination of factors related to Revolution Medicines’ clinical momentum and pipeline strategy. He views the RASolute 302 trial as a major potential value driver, noting that enrollment is complete, the company is closely tracking survival events, and that interim analyses could yield meaningful efficacy signals in the first half of 2026. He also sees limited concern around geographic variability in outcomes, as management emphasized that standards of care in pancreatic cancer are largely harmonized globally, with only minor regional nuances.
In addition, Cheng highlights the strategic design of multiple Phase 3 studies for zoldonrasib in first-line pancreatic cancer, where running two separate trials rather than a single three-arm study offers operational advantages and the ability to target distinct patient segments more efficiently. He further points to the FDA’s CNPV designation for daraxonrasib in pancreatic cancer as an indicator of regulatory interest, which could translate into an accelerated path to market once robust data are available. Taken together, these elements underpin his view that the company is well positioned for important clinical readouts and potential future approvals, supporting a favorable risk-reward profile for RVMD shares.

Cheng covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Revolution Medicines, and Zymeworks. According to TipRanks, Cheng has an average return of 1.3% and a 50.90% success rate on recommended stocks.

In another report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $143.00 price target.